Abstract
Introduction Sudden cardiac death (SCD) is the leading cause of death in patients with myocardial infarction (MI) and can be prevented by the implantable cardioverter defibrillator (ICD). Currently, risk stratification for SCD and decision on ICD implantation are based solely on impaired left ventricular ejection fraction (LVEF). However, this strategy leads to over- and under-treatment of patients because LVEF alone is insufficient for accurate assessment of prognosis. Thus, there is a need for better risk stratification. This is the study protocol for developing and validating a prediction model for risk of SCD in patients with prior MI.
Methods and Analysis The EU funded PROFID project will analyse 23 datasets from Europe, Israel and the US (∼225,000 observations). The datasets include patients with prior MI or ischemic cardiomyopathy with reduced LVEF<50%, with and without a primary prevention ICD. Our primary outcome is SCD in patients without an ICD, or appropriate ICD therapy in patients carrying an ICD as a SCD surrogate. For analysis, we will stack 18 of the datasets into a single database (datastack), with the remaining analysed remotely for data governance reasons (remote data). We will apply 5 analytical approaches to develop the risk prediction model in the datastack and the remote datasets, all under a competing risk framework: 1) Weibull model, 2) flexible parametric survival model, 3) random forest, 4) likelihood boosting machine, and 5) neural network. These dataset-specific models will be combined into a single model (one per analysis method) using model aggregation methods, which will be externally validated using systematic leave-one-dataset-out cross-validation. Predictive performance will be pooled using random effects meta-analysis to select the model with best performance.
Ethics and dissemination Local ethical approval was obtained. The final model will be disseminated through scientific publications and a web-calculator. Statistical code will be published through open-source repositories.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A - protocol paper
Funding Statement
The work described is part of the PROFID project. This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 847999
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Whenever required by national or local regulations all individual participating databases were approved by their respective ethical boards (see below details where this was required). Data Controller approvals were obtained for all other datasets that did not require ethical approval. All data was shared under data sharing agreements, and was handled strictly in adherence to GDPR, European laws and local data safety protocols. Centro Cardiologico Monzino Registry, local IRB details: - Comitato Etico, Centro CARDIOLOGICO Monzino c/o Istituto Europeo di Oncologia Via Ripamonti, 435 20141 MILANO. - Decision: Approved Helios Hospital EHR, local IRB details: - Universitat Leipzig, Medizinische Fakultat, Ethik-Kommission, Kathe-Kollwitz-Str. 82, 04109 Leipzig, Germany - Decision: Ethical approval was given. No objections to the retrospective data analysis as long as the data are anonymised (which they will be). PRE-DETERMINE, local IRB details: - Mass General Brigham IRB, Mass General Brigham, 399 Revolution Drive, Suite 710, Somerville, MA 02145, Tel: 857-282-1900, Fax: 857-282-5693 - IRB Protocol Number: 2007P000840 - Decision: This project has been reviewed and approved by the MGB IRB. During the review of this project, the IRB specifically considered (i) the risks and anticipated benefits, if any, to subjects; (ii) the selection of subjects; (iii) the procedures for obtaining and documenting informed consent; (iv) the safety of subjects; and (v) the privacy of subjects and confidentiality of the data Swedish Registry, local IRB details: - Swedish Ethical Review Authority - Decision: Approved (Dnr 2020-04158)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contributorship statement Gerhard Hindricks and Nikolaos Dagres conceived the overall idea of the PROFID project and are the study principal investigators. Glen P. Martin, Zoher Kapacee and Niels Peek drafted the initial version of this manuscript, with scientific input on the study design and methodology from Artur Akbarov, Le Mai Parkes, Golnoosh Motmedi-Ghahfarokhi, Stephanie Ng, Daniel Sprague, Youssef Taleb, Marcus Ong, Enrico Longato and Chris Miller. All authors critically reviewed the manuscript for scientific content and have approved the final version.
Competing Interests The authors have no conflicts of interest to declare.
Funding The work described is part of the PROFID project. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847999.
Data Availability
We will not be able to share the individual participant data owing to the required data sharing agreements and considerations
